Arrowstreet Capital’s PTC Therapeutics PTCT Stock Holding History

Arrowstreet Capital’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53.4M	Buy	654,382 +542,750	+486%	+$39.2M	0.02%	538
2026 Q1	$7.61M	Sell	111,632 -294,778	-73%	-$20.9M	﹤0.01%	1022
2025 Q4	$30.9M	Buy	406,410 +82,862	+26%	+$6.02M	0.02%	619
2025 Q3	$19.9M	Buy	323,548 +289,548	+852%	+$15.1M	0.01%	732
2025 Q2	$1.66M	Buy	+34,000	New	+$1.61M	﹤0.01%	1495
2021 Q1	–	Sell	-17,678	Closed	-$1.08M	–	2471
2020 Q4	$1.08M	Buy	+17,678	New	+$1.04M	﹤0.01%	1806
2020 Q3	–	Sell	-82,400	Closed	-$4.18M	–	2485
2020 Q2	$4.18M	Buy	+82,400	New	+$4.05M	0.01%	1135
2020 Q1	–	Sell	-154,969	Closed	-$7.44M	–	2066
2019 Q4	$7.44M	Buy	+154,969	New	+$6.59M	0.02%	717
2019 Q2	–	Sell	-34,800	Closed	-$1.31M	–	1647
2019 Q1	$1.31M	Buy	+34,800	New	+$1.17M	﹤0.01%	1240
2018 Q3	–	Sell	-12,214	Closed	-$412K	–	1220
2018 Q2	$412K	Sell	12,214 -12,708	-51%	-$396K	﹤0.01%	941
2018 Q1	$674K	Buy	+24,922	New	+$631K	﹤0.01%	924
2015 Q3	–	Sell	-67,400	Closed	-$3.24M	–	1466
2015 Q2	$3.24M	Buy	+67,400	New	+$3.93M	0.02%	521

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Arrowstreet Capital's PTCT Position: Q2 2026 in Review

Arrowstreet Capital increased its PTC Therapeutics (PTCT) stake by 486% in Q2 2026, buying an estimated $39.2M and bringing the position to 654,382 shares worth $53.4M. The position accounts for 0.02% of the portfolio, ranked #538.

Arrowstreet Capital first reported a position in PTCT in Q2 2015 and has held it in 12 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Arrowstreet Capital held 654,382 shares of PTC Therapeutics worth $53.4M as of Q2 2026.
Arrowstreet Capital bought 542,750 PTC Therapeutics shares in Q2 2026, an estimated $39.2M.
PTC Therapeutics made up 0.02% of Arrowstreet Capital's portfolio in Q2 2026, its #538 holding.
Arrowstreet Capital first reported a position in PTC Therapeutics in Q2 2015 and has held it in 12 quarters since.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.